Puma Biotechnology (NASDAQ:PBYI) shares traded -6.5% down during most recent session to reach at the closing price of $39.27. The stock exchanged hands 1.09 Million shares versus average trading capacity of 1.17 Million shares, yielding a market cap of $1.51 Billion. Wall Street analysts covering the stock are projecting that the stock will reach $43.88 within the next 52-weeks. The mean target projections are based on 8 opinions.

Taking a broader look brokerage firms’ analysts on the street with an expectant view have Puma Biotechnology (NASDAQ:PBYI) high price target of $70 and with a conservative view have low price target of $26.

Citigroup “Maintained” Puma Biotechnology (NASDAQ:PBYI) in a research note issued to investors on 3/01/19 to Buy with price target of $70.

Additionally on 1/17/19 Leerink Swann “Initiates Coverage On” Puma Biotechnology (NASDAQ:PBYI) to Market Perform setting price target at $0 and on 1/03/19 Guggenheim “Downgrades” the stock to Neutral at $0. Furthermore on 11/19/18 Goldman Sachs “Upgrades” the stock to Neutral at $28.

On the other hand the company has Relative Strength Index (RSI 14) of 67.05 along with Average True Range (ATR 14) of 2.21, Consequently Puma Biotechnology (NASDAQ:PBYI)’s weekly and monthly volatility is 5.69%, 5.73% respectively. The company’s beta value is at 0.52.

In terms of Buy, Sell or Hold recommendations, Puma Biotechnology (NASDAQ:PBYI) has analysts’ mean recommendation of 3. This is according to a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.

According to analysts Puma Biotechnology (NASDAQ:PBYI)’s minimum EPS for the current quarter is at $-0.98 and can go high up to $-0.4. The consensus mean EPS for the current quarter is at $-0.68 derived from a total of 9 estimates from the analysts who have weighed in on projected earnings. However the company reported $-0.65 earnings per share for the same quarter during last year.

Previously Puma Biotechnology (NASDAQ:PBYI) reported $-0.8 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.77 by $-0.03. The company posted an earnings surprise of -3.9%.

Puma Biotechnology (NASDAQ:PBYI)’s revenue estimates for the current quarter are $66.53 Million according to 7 number of analysts, for the current quarter the company has high revenue estimates of $72 Million in contradiction of low revenue estimates of $63 Million. For the current year the company’s revenue estimates are $297.7 Million compared to low analyst estimates of $284.5 Million and high estimates of $317.13 Million according to 9 number of analysts.

Currently Puma Biotechnology (NASDAQ:PBYI)’s shares owned by insiders are 11.2%, whereas shares owned by institutional owners are 93.8%. However the six-month change in the insider ownership was recorded -0.51%, as well as three-month change in the institutional ownership was recorded -1.19%.

Puma Biotechnology (NASDAQ:PBYI)’s trailing twelve month revenues are $251 Million, whereas its price to sales ratio for the same period is 6.02. Its book value per share for the most recent quarter is $0.9 while its price to book ratio for the same period is 43.63, as for as the company’s cash per share for the most recent quarter is $4.3, however its price to cash per share ratio for the same period is 9.13. The stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0.